皮下英夫利西单抗按病变部位的内镜应答:LIBERTY-CD研究事后分析
该事后分析基于III期LIBERTY-CD试验,纳入329例对静脉英夫利西单抗诱导治疗第10周有应答的中重度活动性克罗恩病患者,随机接受皮下英夫利西单抗120mg每2周或安慰剂维持治疗。至第54周,皮下英夫利西单抗较安慰剂显著改善所有疗效终点,且疗效不受病变部位影响,包括回肠末端在内的各肠段内镜应答均更优。
要点
- 皮下英夫利西单抗维持治疗第54周在所有疗效终点上显著优于安慰剂
- 疗效在回肠为主型和结肠为主型病变之间相似,不受病变部位影响
- 包括回肠末端在内的所有回结肠肠段内镜应答均优于安慰剂
核心结论
- 皮下英夫利西单抗维持治疗无论病变部位如何均优于安慰剂,在包括回肠末端在内的各肠段显示一致疗效。
研究设计与样本
- III期LIBERTY-CD试验的事后分析,纳入329例对静脉英夫利西单抗诱导治疗第10周有应答的中重度活动性克罗恩病患者,随机接受皮下英夫利西单抗120mg每2周或安慰剂维持治疗,随访至第54周。
主要发现
- 329例患者中,结肠为主型占52.6%(n=173),回肠为主型占47.4%(n=105),两组基线特征相当。
- 第54周时,皮下英夫利西单抗在所有疗效终点上显著优于安慰剂,尽管安慰剂组患者可能仍存在静脉英夫利西单抗诱导治疗的残留效应。
- 无论病变部位如何,疗效相似;在两个部位组中,第54周临床缓解和内镜应答均与第14周和第54周较高的血清英夫利西单抗水平相关。
- 第54周时,皮下英夫利西单抗组在所有回结肠肠段(包括回肠末端)的内镜应答均优于安慰剂,各肠段疗效效应量一致。
临床怎么用
- 对于中重度活动性克罗恩病患者,皮下英夫利西单抗维持治疗可考虑用于不同病变部位,包括回肠末端病变。
局限性
- 为事后分析,安慰剂组患者可能仍存在静脉英夫利西单抗诱导治疗的残留效应,可能影响组间比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The efficacy of targeted therapies for patients with Crohn's disease (CD) varies by disease location, with the terminal ileum being the most challenging segment to treat despite its frequent involvement. We investigated the efficacy of subcutaneous infliximab (IFX SC) in patients with moderately to severely active CD according to disease location using data from the phase III LIBERTY-CD trial. METHODS: This analysis included week (W) 10 responders to intravenous IFX induction therapy who were randomized to receive IFX SC 120 mg every 2 weeks or placebo (PBO) during maintenance therapy. Patients were grouped according to baseline disease location (ileum-dominant or colon-dominant), and outcomes were assessed up to W54. Endoscopic response was also evaluated at the segmental level. Factors associated with W54 outcomes were assessed according to disease location. RESULTS: Among 329 patients, 52.6% had colon-dominant CD (n = 173), and 47.4% had ileum-dominant CD (n = 105). Baseline characteristics were comparable between groups. At W54, IFX SC significantly improved all efficacy endpoints vs PBO, even though PBO-treated patients may have experienced residual treatment effects from intravenous IFX induction therapy. Treatment effects were similar regardless of disease location. In both location groups, clinical remission and endoscopic response at W54 correlated with higher serum IFX levels at W14 and W54. Endoscopic responses at W54 were greater with IFX SC vs PBO across all ileocolonic segments, including the terminal ileum, with consistent treatment effect sizes observed throughout each segment. CONCLUSIONS: Although ileal disease is often more treatment resistant, IFX SC maintenance therapy was effective vs PBO regardless of disease location, demonstrating consistent efficacy across segments including the terminal ileum.
引用
- Sands BE, Schreiber S, Dubinsky MC, et al. Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study. Clin Gastroenterol Hepatol. 2025. PMID: 41285264. doi:10.1016/j.cgh.2025.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。